<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03239119</url>
  </required_header>
  <id_info>
    <org_study_id>rE-4201706/PRO</org_study_id>
    <nct_id>NCT03239119</nct_id>
  </id_info>
  <brief_title>The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind,Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) and Safety of rE-4 in Subjects With Type 2 Diabetes Mellitus Treated With Metformin, a Sulfonylurea, or Metformin and Sulfonylurea Combination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is a randomized, double-blind,controlled trial. 456 Chinese subjects with Type
      2 Diabetes Mellitus will be enrolled in the trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on
      glucose control of rE-4 as compared to placebo in patients with type 2 diabetes. Patients
      will be randomized into one of two rE-4 treatment arms or to placebo treatment and will
      continue with their required existing diabetes medications (metformin, a sulfonylurea or
      metformin and a sulfonylurea combination) throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2017</start_date>
  <completion_date type="Anticipated">January 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c from Baseline to Week 30</measure>
    <time_frame>Baseline (Day 1) to Week 30</time_frame>
    <description>Change in HbA1c from Baseline (Day 1) to study termination (Week 30)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of subjects achieving HbA1c target values of &lt; 7% and ≤ 6.5% by Week 30</measure>
    <time_frame>Baseline (Day 1) and Week 30</time_frame>
    <description>The number of subjects achieving HbA1c target values of &lt; 7% and ≤ 6.5% by study termination (Week 30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight from Baseline to each intermediate visit and Week 30</measure>
    <time_frame>Baseline (Day 1), Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 30</time_frame>
    <description>Change in body weight (kg) from Baseline to each intermediate visit and Week 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FPG from Baseline to each intermediate visit and Week 30</measure>
    <time_frame>Baseline (Day 1), Week 2, Week 4, Week, 6, Week 12, Week 18, Week 24, Week 30</time_frame>
    <description>Change in Fasting Plasma Glucose from Baseline to each intermediate visit and Week 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 7-SMBG from Baseline to Week 16，Week 24 and Week 30</measure>
    <time_frame>Baseline, Week 16，Week 24 and Week 30</time_frame>
    <description>Change in glucose measurements before and 2h after the start of the morning,midday,and evening meals, and at bedtime from Baseline to Week 16，Week 24 and Week 30</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">456</enrollment>
  <condition>Type2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>rE-4 5 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo, then rE-4 5 mcg, then rE-4 5 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rE-4 10 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo, then rE-4 5 mcg, then rE-4 10 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 5 mcg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 5 mcg, then Placebo 5 mcg, then Placebo 5 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 10 mcg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 5 mcg, then Placebo 5 mcg, then Placebo 10 mcg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rE-4 5 mcg</intervention_name>
    <description>Placebo Lead In (5 mcg) for 4 weeks / rE-4 5 mcg for 4 weeks / rE-4 5 mcg for 26 weeks - All are subcutaneously injected twice daily</description>
    <arm_group_label>rE-4 5 mcg</arm_group_label>
    <other_name>rExenatide-4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rE-4 10 mcg</intervention_name>
    <description>Placebo Lead In (5 mcg) for 4 weeks / rE-4 5 mcg for 4 weeks / rE-4 10 mcg for 26 weeks - All are subcutaneously injected twice daily</description>
    <arm_group_label>rE-4 10 mcg</arm_group_label>
    <other_name>rExenatide-4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo 5 mcg</intervention_name>
    <description>Placebo Lead In (5 mcg) for 4 weeks / Placebo 5 mcg for 4 weeks / Placebo 5 mcg for 26 weeks - All are subcutaneously injected twice daily</description>
    <arm_group_label>Placebo 5 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo 10 mcg</intervention_name>
    <description>Placebo Lead In (5 mcg) for 4 weeks / Placebo 5 mcg for 4 weeks / Placebo 10 mcg for 26 weeks - All are subcutaneously injected twice daily</description>
    <arm_group_label>Placebo 10 mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. T2DM

          2. 7.0% ≤ HbA1c ≤ 11.0% at screening

          3. FPG ≤13.8 mmol/L

          4. 19 kg/m2 ＜ BMI ＜35.0 kg/m2 at screening

          5. All subjects provided written informed consent before participation

        Exclusion Criteria:

          1. T1DM

          2. Patients treated previously with Exenatide or GLP-1 similar

          3. At screening visit alanine aminotransferase (ALT) or alkaline phosphatase (AST) more
             than 2.5 ULN

          4. At screening visit estimated glomerular filtration rate (eGFR) ≤ 60 mL/min or
             Triglyceride(TG)≥ 5 mmol/L

          5. Pancreatitis, cholecystitis, gallstones and other gastrointestinal diseases

          6. Within the last 12 months prior to screening visit: history of stroke, myocardial
             infarction, unstable angina, or heart failure requiring hospitalization. Planned
             coronary, carotid or peripheral artery revascularisation procedures to be performed
             during the study period

          7. History of digestive diseases (e.g.pancreatitis, cholecystitis or gallstones)

          8. Patients with severe renal impairment or end-stage renal disease

          9. Uncontrolled or inadequately controlled hypertension (systolic blood pressure above
             180 mmHg or diastolic blood pressure above 110 mmHg) at screening visit.

         10. Use of weight loss drugs within 3 months prior to screening visit

         11. Have been treated with exogenous insulin, α-glucosidase, corticosteroid, DPP-4
             inhibitor or pramlintide acetate within the 3 months prior to screening.

         12. Severe gastrointestinal disease (e.g., gastroparesis)

         13. Pregnancy or lactation, women of childbearing potential with no effective
             contraceptive method

         14. Participant who participated in any drug clinical trial within the last 3 months prior
             to screening visit

         15. History of severe hypersensitivity to rExenatide-4 or any product components
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>linong Ji, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>linong Ji, Ph.D</last_name>
    <phone>+86-01088325578</phone>
    <email>jiln@bjmu.edu.cn</email>
  </overall_contact>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2017</study_first_submitted>
  <study_first_submitted_qc>August 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2017</study_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rE-4</keyword>
  <keyword>Exenatide</keyword>
  <keyword>Metformin</keyword>
  <keyword>Sulfonylurea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

